Nine of 11 patients in new brain cancer trial saw their tumors shrink by at least half. One really beat the odds.

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Techniques that cause multipotent adult mesenchymal stem cells (MSCs) to differentiate ... activities in the OA joint. Targeted gene therapy might further enhance these activities of MSCs.

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

A quick questionnaire and a swab from the inside of her cheek, and Delaney Hilferty was pretty sure her duty was done. It was ...

Pediatric cataract surgeries are more costly than adult procedures, with significant nonsurgical expenses like anesthesia and ...

Researchers led by Osaka University in Japan have conducted the first human trial using induced pluripotent stem-cell-derived ...

PHAT is a facial rejuvenation therapy that combines nanofat and its stem cells with PRP for anti-aging that lasts for more ...

An immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant in a Stanford ...